The global antidepressants drugs, devices and therapies market was valued at $16911 million in 2018 & is estimated to generate net revenue of approximately $19712 million by 2027, growing at a CAGR of 2.12%. Depression has become a major concern worldwide and is a significant cause of various disorders such as sleeping disorders, overeating, sleep apnoea and so on. According to the W.H.O., depression is the fourth leading cause of mental disability across the world and is expected to become the second leading cause by 2020 after cardiac diseases. More than 350 million people worldwide suffer from depression globally, and this number is increasing at a rate of 20% every year. Depression is an extreme condition of mental disorder which is generally long-lasting in nature and usually different from the regular mood swings and emotions. In severe cases, it may lead to committing suicide. Depression is generally driven by disturbing life events, certain medications, and excessive use of a drug. Certain predominant symptoms of depression include a general loss of interest, lack of energy, and the inability to experience pleasure. A person with depression typically withdraws from or becomes impaired in his social interactions.

Depression is one of the common mental disorders across the globe specifically in the US. Various researches have shown the root cause of the depression are environmental, genetic, psychological factor and biological. Current studies have shown that children and adolescents are more prone to depression as compared to an adult person. The high level of anxiety among children is one of the major factors which is resulting in a rise in the prevalence of depression in children.

Global antidepressants drugs, devices and therapies market is primarily driven by the following factors:

• Rise in the number of depression patients
• Increase in aging population
• Rising consciousness of depression as a medical disorder
• Surge in sales of antidepressants

To know more about this report, request a free sample copy.

The important driver is a rise in the number of depression patients. The global prevalence of depression and depressive symptoms have been increasing in recent decades. The lifetime prevalence of depression ranges from 20% to 25% in women and 7% to 12% in men. Depression is a significant determinant of quality of life and survival that accounted for approximately 50% of psychiatric consultations and 12% of all hospital admissions recently. It is a significant type of comorbidity of chronic medical disorders.

The antidepressants drugs, devices and therapies market is segmented on the basis of devices where they are further classified into deep brain stimulators, Fisher Wallace stimulators, transcranial magnetic stimulator and others. Deep brain stimulator is a neurological procedure, wherein a neurological device (neurostimulator device similar to the heart pacemaker) is implanted in the brain. The implant device emits electrical impulses via electrodes within the device targeting specific regions of the brain. Specific areas of the brain are targeted using magnetic resonance imaging (MRI) and computed tomography (CT). They are mainly used to treat neurological movement disorders.

High cost for depression therapies, patent expiration faced by the companies and delay in product launches are the major factors hindering the antidepressants drugs, devices and therapies market. Drug makers witness a downfall of almost 90% of their revenue as soon as they lose patent protection. With the patent expiration, other companies get the rights to produce low-cost generics. Generic market slows down the growth rate of a drug. Currently, generics are almost 30% of the total antidepressants drug markets.

The global antidepressants drugs, devices and therapies market segments include drugs, devices, therapies and region.

Antidepressants drugs are segmented into:

• Serotonin and norepinephrine reuptake inhibitors (SNRIs)
• Tricyclic antidepressants (TCA)
• Monoamine oxidase inhibitors (MAOIs)
• Atypical antidepressants
• Selective Serotonin Reuptake Inhibitors
• Benzodiazepines
• Anticonvulsants
• Beta-Blockers
• Others

Devices is sub-segmented into:

• Deep Brain Stimulators
• Fisher Wallace Stimulators
• Transcranial Magnetic Stimulator
• Others

Therapies is sub-segmented into:

• Cognitive Behavior Therapy (CBT)
• Electroconvulsive Therapy (ECT)
• Rational emotive behavior therapy (REBT)
• Others

Geographically, the global antidepressants drugs, devices and therapies market has been segmented by four major regions, which include:

• North America Antidepressants Drugs, Devices and Therapies Market – The United States of America, Canada
• Asia Pacific Antidepressants Drugs, Devices and Therapies Market – China, India, Japan, Australia, South Korea, and RoAPAC
• Europe Antidepressants Drugs, Devices and Therapies Market – the UK, Spain, Germany, France, Italy, Russia and RoE
• Rest of World- Latin America & MEA

The North America region was the highest contributor to the global market. The countries considered in the North America region are the US and Canada.

Depression is the most serious mental disorder in North America. North America is the largest market in terms of diagnosed patients, devices manufacturers and the number of psychiatrists and psychologists. The growth in the drug market for depression in North America is backed by the developed healthcare system and growing mental health treatment expenditure in the regional countries. Federal agencies and private firms equally participate in providing access to the best medical facilities to the consumers.

The major market players of the global antidepressants drugs, devices and therapies market are:

• Pfizer
• Eli Lilly and Company
• GlaxoSmithKline
• Allergan PLC
• Others companies

Company profiles cover the analysis of important players. These companies are using organic and inorganic strategies for growth. For instance, in January 2017, Allergan acquired Lysosomal Therapeutics which delivers cures for neurodegenerative diseases.

Key findings of the global antidepressants drugs, devices and therapies market:

• Serotonin and norepinephrine reuptake inhibitors (SNRIS) is the dominant drug in the antidepressants market.
• Deep brain stimulator is expected to grow fast among other devices over the forecast period.
• Cognitive behavior therapy (CBT) is the largest contributor to the antidepressants therapies market.